Interim data from a Phase 2 study of SNT-5505 in myelofibrosis patients shows safety, tolerability, and significant symptom and spleen volume improvements over 52 weeks. SNT-5505, combined with RUX, demonstrated durable benefits, with 80% of evaluable patients achieving symptom relief by Week 38 and spleen volume reductions in 82%. The study, involving 16 patients, highlights SNT-5505's potential for long-term benefits in MF treatment.